SPONSOR
Jonsson Comprehensive Cancer Center
Total Trials
11
Recruiting
11
Phases
Phase 2, Phase 1, Phase 2, Phase 1, Phase 3
Conditions studied: Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Invasive Breast CarcinomaLocalized Estrogen Receptor-Positive Breast CarcinomaLocalized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast CarcinomaDiffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed LymphomaSecondary Central Nervous System Lymphoma
Jonsson Comprehensive Cancer Center is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Jonsson Comprehensive Cancer Center
How many clinical trials has Jonsson Comprehensive Cancer Center sponsored?
ClinicalMetric currently tracks 11 clinical trials sponsored by Jonsson Comprehensive Cancer Center, of which 11 are actively recruiting participants. These trials cover conditions including Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Jonsson Comprehensive Cancer Center research focus on?
Jonsson Comprehensive Cancer Center clinical trials span Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Jonsson Comprehensive Cancer Center clinical trial?
To participate in a Jonsson Comprehensive Cancer Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Jonsson Comprehensive Cancer Center trials with current recruitment status updated daily.
Clinical Trials by Jonsson Comprehensive Cancer Center
NCT07191717 Phase 2
Recruiting
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Anatomic Stage I Breast Cancer AJCC v8
NCT05256641 Phase 1, Phase 2
Recruiting
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
NCT07619313 Phase 1
Recruiting
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Borderline Resectable Pancreatic Ductal Adenocarcinoma
NCT05558904 Phase 1, Phase 2
Recruiting
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Lung Adenocarcinoma
NCT07293585 Phase 3
Recruiting
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Prostate Cancer
NCT04712851 Phase 2
Recruiting
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia
NCT06216249 Phase 2
Recruiting
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Prostate Carcinoma
NCT06113016 Phase 2
Recruiting
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8
NCT03603223 Phase 2
Recruiting
Pembrolizumab in Treating Participants With Leukoplakia
Erythroleukoplakia
NCT07185165 Phase 2
Recruiting
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
Prostate Carcinoma
NCT06538337
Recruiting
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
Endometrial Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology